Create Free Account

By creating account you will get access to hot stocks & personalised emails

Percheron Therapeutics Limited

Healthcare AU PER

0.082AUD
-0.003(3.53%)

Last update at 2024-11-13T05:10:00Z

Day Range

0.080.09
LowHigh

52 Week Range

0.050.14
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap81.91M
  • Volume1237805
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.90036M
  • Revenue TTM2.97M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 1.55M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -11.37983M -5.81181M -8.06064M -5.90820M -2.94450M
Minority interest - - - - -
Net income -11.37983M -5.83408M -8.06719M -5.89021M -2.30586M
Selling general administrative 3.05M 2.92M 3.56M 4.46M 1.68M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.45M
Reconciled depreciation 0.10M 0.09M 0.10M 0.11M 0.00538M
Ebit -13.34497M -7.61123M -8.68328M -6.66629M -3.58314M
Ebitda -13.24978M -7.52201M -8.57996M -6.55869M -3.57776M
Depreciation and amortization 0.10M 0.09M 0.10M 0.11M 0.00538M
Non operating income net other - - - - -
Operating income -13.34497M -7.61123M -8.68328M -6.66629M -3.58314M
Other operating expenses 13.34M 7.61M 8.68M 6.67M 3.58M
Interest expense - 0.02M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.38M 0.03M 0.00418M 0.01M 0.01M
Net interest income 0.38M 0.02M -0.00655M -0.01254M 0.07M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.37677M 0.02M 0.00655M -0.01799M -0.63864M
Total revenue 0.38M 0.03M 0.00418M 0.03M 0.07M
Total operating expenses 13.34M 7.61M 8.68M 6.67M 3.58M
Cost of revenue - - - - 0.14M
Total other income expense net 1.59M 1.80M 0.62M 0.76M 0.64M
Discontinued operations - - - - -
Net income from continuing ops -11.37983M -5.81181M -8.06064M -5.90820M -2.94450M
Net income applicable to common shares -11.37983M -5.81181M -8.06064M -5.90820M -2.94450M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 14.53M 12.84M 22.44M 7.00M 5.35M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 1.47M 0.53M 0.67M 0.26M
Total liab 5.17M 2.87M 1.30M 1.27M 0.82M
Total stockholder equity 9.36M 9.98M 21.14M 5.73M 4.53M
Deferred long term liab - - - - -
Other current liab - 1.79M 0.83M 0.89M 0.69M
Common stock - 98.26M 98.13M 77.03M 69.15M
Capital stock 109.37M 98.26M 98.13M 77.03M 69.15M
Retained earnings -101.73024M -92.28922M -80.90939M -75.09758M -67.03694M
Other liab - 0.00706M 0.00113M 0.00012M -
Good will - - - - -
Other assets - - - - -
Cash 11.87M 10.97M 19.23M 6.02M 4.06M
Cash and equivalents - - - 6.02M 4.06M
Total current liabilities 5.15M 2.81M 1.16M 1.05M 0.80M
Current deferred revenue - -0.09408M -0.09409M -0.07944M -0.11257M
Net debt - -10.82516M -19.00578M -5.71356M -3.92418M
Short term debt - 0.09M 0.09M 0.08M 0.11M
Short long term debt - - - - -
Short long term debt total - 0.14M 0.23M 0.31M 0.14M
Other stockholder equity - 4.00M 3.92M 3.79M 2.72M
Property plant equipment - 0.15M 0.22M 0.30M 0.14M
Total current assets 14.47M 12.69M 22.22M 6.70M 5.21M
Long term investments - - - - -
Net tangible assets - 9.98M 21.14M 5.73M 4.53M
Short term investments - 10.50M 18.42M - -
Net receivables 0.08M 1.66M 1.84M 0.60M 0.69M
Long term debt - - - - -
Inventory - 0.00000M 0.00000M 0.00000M 0.21M
Accounts payable 3.73M 1.02M 0.33M 0.16M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 4.00M 3.92M 3.79M 2.42M
Additional paid in capital - - - - -
Common stock total equity - - - - 69.15M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.15079M -0.21670M -0.30200M -0.13812M
Deferred long term asset charges - - - - -
Non current assets total 0.06M 0.15M 0.22M 0.30M 0.14M
Capital lease obligations 0.04M 0.14M 0.23M 0.31M 0.14M
Long term debt total - 0.05M 0.13M 0.23M 0.02M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.02929M -0.00391M -0.00835M -0.01026M 2.40M
Change to liabilities 1.76M 0.03M 0.22M -0.25981M 0.22M
Total cashflows from investing activities -0.02929M -0.00391M -0.00835M -0.01026M 2.40M
Net borrowings -0.08530M -0.07944M -0.08238M -0.09789M -0.09789M
Total cash from financing activities -0.08530M 21.02M 7.80M 5.11M 1.53M
Change to operating activities 0.77M -0.99621M 0.45M 0.03M 0.07M
Net income -11.37983M -5.81181M -8.06064M -5.90820M -2.94450M
Change in cash -8.26592M 13.21M 1.96M 1.16M 1.00M
Begin period cash flow 19.23M 6.02M 4.06M 2.90M 1.90M
End period cash flow 10.97M 19.23M 6.02M 4.06M 2.90M
Total cash from operating activities -8.15133M -7.80517M -5.83416M -3.94536M -2.92844M
Issuance of capital stock - 22.59M 8.50M 5.49M 1.60M
Depreciation 0.10M 0.09M 0.10M 0.11M 0.00538M
Other cashflows from investing activities - - - 0.00000M 2.40M
Dividends paid - 0.08M 0.08M 0.10M -
Change to inventory - - - - -
Change to account receivables 0.34M -1.23972M 0.09M -0.33976M -0.27531M
Sale purchase of stock 0.00000M -1.48520M -0.61415M -0.28515M -0.06708M
Other cashflows from financing activities -0.02929M 0.08M 0.08M 0.10M 2.40M
Change to netincome 0.26M 0.12M 1.37M 2.42M 2.42M
Capital expenditures 0.03M 0.00391M 0.00835M 0.01M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.34M -1.23972M 0.09M -0.33976M 0.36M
Stock based compensation 0.21M 0.12M 1.37M 2.42M -
Other non cash items 3.13M -2.08257M 2.12M 1.86M 2.94M
Free cash flow -8.18062M -7.80908M -5.84251M -3.95562M -0.01026M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PER
Percheron Therapeutics Limited		 -0.003 3.53% 0.08 - - 27.59 8.75 347.00 -4.4641
AFP
AFT Pharmaceuticals Ltd		 -0.02 0.78% 2.55 17.71 19.08 1.35 3.31 1.56 10.94
VLS
Vita Life Sciences Ltd		 - -% 2.09 12.06 - 1.46 2.42 1.15 6.64
LV1
Live Verdure Ltd		 0.03 4.29% 0.73 - - 52.75 39.01 42.66 -5.083
VIT
Vitura Health Limited		 -0.003 3.06% 0.10 9.50 - 0.44 1.46 0.45 7.74

Reports Covered

Stock Research & News

View All

Profile

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Percheron Therapeutics Limited

L30, Collins Place, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD CEO, MD & Director NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Joint Company Sec. 1959
Dr. George Tachas Director of Drug Discovery & Patents NA
Ms. Nuket Desem Director of Clinical and Regulatory affairs NA
Dr. Anthony Filippis Chief Commercial Officer NA
Ms. Alicia Mellors Joint Company Sec. NA
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA CEO, MD & Director 1973
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Joint Company Secretary 1959
Dr. Anthony Filippis Chief Operating Officer NA
Ms. Alicia Mellors Joint Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.